

## **Renal Biomarkers: Technologies and Global Markets**

Market Research Report | 2022-12-16 | 93 pages | BCC Research

### **AVAILABLE LICENSES:**

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

### **Report description:**

Description

Report Scope:

This report incorporates an in-depth analysis of the renal biomarker market, including market estimations and trends through 2021. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the CAGR for renal biomarkers.

The scope of the report extends only to renal biomarker consumables and not devices used to study renal biomarkers. All types of renal biomarkers have been considered in research, clinical trials and for diagnostic purposes.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World (RoW) region. For market estimates, data is provided for 2021 as the base year, 2022 and forecast through year-end 2027.

Report Includes:

- 41 data tables and 24 additional tables
- A detailed overview and up-to-date analysis of the global markets for renal biomarkers
- Analyses of the global market trends, with market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for renal biomarkers market, and corresponding market share analysis by assay type, application, end user, and region

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott-international.com](mailto:support@scott-international.com)

[www.scott-international.com](http://www.scott-international.com)

- Updated information on market drivers and opportunities for renal biomarkers, key shifts, regulations and industry specific challenges, and other demographic factors that will shape the market demand over the coming years (2022-2027)
- Identification of the companies best positioned to meet the demand owing to their proprietary technologies, product launches, mergers and acquisitions, and other market strategic advantages
- Review of recent industry structure for biomarkers, R&D activities, and analysis of the competitive landscape based on recent developments and segmental revenues
- Patent activity and review of patent grants for biomarkers and related technologies
- Descriptive company profiles of the market leading players, including BioMerieux, Gentian Diagnostic, Proteomics International, Thermo Fisher Scientific, SphingoTec, and BioPorto

## Executive Summary

### Summary:

The global market for renal biomarkers reached \$REDACTED billion in 2021. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to reach \$REDACTED billion during the forecast period.

The renal biomarker market is growing at a steady pace due to the increasing prevalence and incidence of the two major kidney diseases: acute kidney injury (AKI) and chronic kidney disease (CKD). These diseases increase hospitalization time, leading to higher costs and morbidity. Early identification of such diseases leads to better treatment, which is possible through biomarkers.

COVID-19 has had a huge impact in increasing the incidence of kidney diseases. Long-term COVID patients have a higher incidence of AKI or CKD. The prevalence of lifestyle diseases such as diabetes and hypertension is also rising. These are closely associated with kidney disorders and malfunction. These diseases are currently the 16th leading cause of death but are expected to be fifth leading by 2030.

The traditional biomarkers used for detecting AKI and CKD have many disadvantages compared to new and novel biomarkers. New biomarkers are being studied and discovered, as there is a gap for an ideal renal biomarker. There is no single renal tumor biomarker that can be pursued by the industry.

### **Table of Contents:**

Table of Contents

Chapter 1 Introduction

1.1 Study Goals and Objectives

1.2 Reasons for Doing this Study

1.3 What's New in this Report

1.4 Scope of Report

1.5 Information Sources

1.6 Methodology

1.7 Geographic Breakdown

1.8 Analyst's Credentials

1.9 BCC Custom Research

1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

3.1 Introduction

3.1.1 Kidneys

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3.1.2 Renal Biomarkers
- 3.1.3 Definition
- 3.2 Market Dynamics
  - 3.2.1 Drivers
  - 3.2.2 Restraints
  - 3.2.3 Opportunities
- 3.3 Regulatory Process for Biomarkers
  - 3.3.1 European Medicines Agency
  - 3.3.2 Biomarkers Qualified by the FDA
- Chapter 4 Impact of COVID-19 Pandemic
  - 4.1 Impact of COVID-19 on Renal Biomarker Market
    - 4.1.1 Increased Incidence of AKI
    - 4.1.2 Other Diseases
  - 4.2 Chronic Dialysis Patients
    - 4.2.1 Kidney Transplant Recipients
- Chapter 5 Global Renal Biomarker Market by Type
  - 5.1 Overview
  - 5.2 Filtered Renal Biomarkers (Impaired Tubular Reabsorption)
    - 5.2.1 Albumin
    - 5.2.2 Cystatin C
    - 5.2.3 Beta-2 Microglobulin
  - 5.3 Upregulated Biomarkers
    - 5.3.1 KIM-1 Kidney Injury Molecule
    - 5.3.2 Neutrophil Gelatinase Associated Lipocalin
    - 5.3.3 Clusterin
    - 5.3.4 Interleukin-18
    - 5.3.5 Netrin-1
  - 5.4 Preformed
    - 5.4.1 Alkaline Phosphatase
    - 5.4.2 Gamma-Glutamyl Transpeptidase
    - 5.4.3 Glutathione S-Transferase
    - 5.4.4 N-acetyl-?-D Glucosaminidase
    - 5.4.5 Liver-Type Fatty Acid-Binding Protein
    - 5.4.6 Tissue Inhibitor of Metalloprotease-2 and Insulin-Like Growth Factor-binding Protein 7
  - 5.5 Other Biomarkers
    - 5.5.1 Blood Urea Nitrogen
    - 5.5.2 Serum Creatinine
    - 5.5.3 Downregulated
- Chapter 6 Global Market for Renal Biomarkers by Region
  - 6.1 North America
    - 6.1.1 United States
    - 6.1.2 Canada
  - 6.2 Europe
    - 6.2.1 Germany
    - 6.2.2 Italy
    - 6.2.3 France
    - 6.2.4 Spain

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

6.2.5 United Kingdom  
6.2.6 Rest of Europe  
6.3 Asia-Pacific  
6.3.1 Australia  
6.3.2 Japan  
6.3.3 China  
6.3.4 Rest of Asia  
6.4 Rest of the World  
Chapter 7 Renal Biomarker Market by End User  
7.1 Hospitals  
7.2 Research Centers  
7.3 Other End Users  
Chapter 8 Renal Biomarker Market by Technique  
8.1 Overview  
8.2 Enzyme Linked Immunosorbent Assay  
8.3 Particle-Enhanced Turbidimetric Immunoassays  
8.4 Colorimetric Assays  
8.5 Chemiluminescent Enzyme Immunoassays  
8.6 Other Detection Methods  
Chapter 9 Competitive Landscape  
Chapter 10 Company Profiles  
ABBOTT LABORATORIES  
BECKMAN COULTER INC.  
BIOMERIEUX  
BIOPORTO A/S  
BIO-RAD  
ENZO BIOCHEM INC.  
GENTIAN DIAGNOSTIC AB  
HYTEST LTD.  
NEPHROSANT  
Nexelis  
PROTEOMICS INTERNATIONAL LABORATORIES LTD.  
RANDOX LABORATORIES LTD.  
ROCHE (F. HOFFMANN-LA ROCHE AG)  
SPHINGOTEC  
THERMO FISHER SCIENTIFIC  
Chapter 11 Patent Review  
Chapter 12 Clinical Trial Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Renal Biomarkers: Technologies and Global Markets**

Market Research Report | 2022-12-16 | 93 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

